murine pca cell line rm1  (ATCC)

Journal: Biochemical pharmacology

Article Title: PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

doi: 10.1016/j.bcp.2020.113943

Figure Lengend Snippet: (A) Three-dimensional and longitudinal cross-sectional μCT images of the tibia from control and RM1 cell administered mice post-IPA-3 treatment. Analysis of trabecular bone (indicated by arrows) demonstrates significant loss of trabecular bone in RM1-injected tibia which was blunted upon treatment with 5 mg/kg/day IPA-3 (n=10). (B-C) A plot showing significantly reduced bone volume percentage and bone marrow density of trabecular area with RM1 cell injection into the tibia, which was rescued with IPA-3 treatment for 15 days. (D-E) A plot showing the significantly reduced trabecular number with RM1 cell injection into the tibia, which was rescued with IPA-3 treatment for 15 days (n=10). The trabecular thickness did not change between groups indicating that cancer cells do not affect trabecular thickness in the trabecular section of tibia. Data are presented as mean ± SEM. *p < 0.05; $p < 0.01; #p < 0.001. Unpaired Student’s t-test was used to compare between two groups and One-way ANOVA-Ordinary for more than two groups. BV=Bone Volume, TV=Tissue Volume, BMD=Bone Marrow Density.

Article Snippet: Cell culture The murine metastatic PCa RM1 cell line (CRL-3310) was obtained from ATCC (Manassas, VA).

Techniques: Control, Injection

Journal: Biochemical pharmacology

Article Title: PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

doi: 10.1016/j.bcp.2020.113943

Figure Lengend Snippet: (A) Representative Western blot images and band densitometry analysis of images showing the PAK1 expression in murine PCa (RM1) cells treated with different doses of IPA-3 for 72 h (n=5). (B) Bar graph showing a dose-dependent reduction in RM1 cell MTT staining by IPA-3 treatment for 72 h (n=6). (C-D) Representative images from the RM1 cell monolayer scratch assay (0 and 24 h) and a bar graph showing the migration of PCa cells in the presence and absence of PAK1 inhibitor IPA-3 after 24 h compared to the DMSO-treated control group (N=5). (E-F) Representative H&E stained lung section images showing a significant decrease in lung colonization in IPA-3 treated group compared to the control group (n=5). Data are presented as mean ± SEM. *p < 0.05; $p < 0.01. Unpaired Student’s t-test was used to compare between two groups and One-way ANOVA-Ordinary for more than two groups.

Article Snippet: Cell culture The murine metastatic PCa RM1 cell line (CRL-3310) was obtained from ATCC (Manassas, VA).

Techniques: Western Blot, Expressing, Staining, Wound Healing Assay, Migration, Control

Journal: Biochemical pharmacology

Article Title: PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

doi: 10.1016/j.bcp.2020.113943

Figure Lengend Snippet: (A) Representative H&E stained images of mouse tibiae showing significantly reduced bone resorption and loss of bone mass induced by RM1 cells in IPA-3-treated mice compared to DMSO control. [Arrows indicate loss of bone mass] (n=10). (B) Bar graph showing the significantly higher percentage of tibia bone area in IPA-3-treated mice compared to the control group (n=10). Data are presented as mean ± SEM. $p < 0.01; #p < 0.001. Unpaired Student’s t-test was used to compare between two groups and One-way ANOVA-Ordinary for more than two groups.

Article Snippet: Cell culture The murine metastatic PCa RM1 cell line (CRL-3310) was obtained from ATCC (Manassas, VA).

Techniques: Staining, Control

Journal: Biochemical pharmacology

Article Title: PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

doi: 10.1016/j.bcp.2020.113943

Figure Lengend Snippet: (A) Control (PBS) and RM1 cell-administered mice post-experiment indicating changes in trabecular bone loss in the presence and absence of IPA-3. Analysis indicated a loss in trabecular mass was significantly inhibited by treatment with 5 mg/kg/day IPA-3 [Arrows indicate the bone loss] (n=10). (B-C) Graphs showing a significant reduction in the loss of tissue volume and bone volume with RM1 cell-injection into the tibia, and its reversal with IPA-3 treatment for 15 days (N=10). Data are presented as mean ± SEM. *p < 0.05; $p < 0.01; #p < 0.001. Unpaired Student’s t-test was used to compare between two groups and One-way ANOVA-Ordinary for more than two groups.

Article Snippet: Cell culture The murine metastatic PCa RM1 cell line (CRL-3310) was obtained from ATCC (Manassas, VA).

Techniques: Control, Injection

Journal: Biochemical pharmacology

Article Title: PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

doi: 10.1016/j.bcp.2020.113943

Figure Lengend Snippet: (A-B) Graphs indicating that while cortical tissue volume was similar in all groups, cortical bone volume was significantly reduced with intra-tibial RM1 cell injection, which was rescued by IPA-3 treatment. This indicates the loss of bone mass induced by cancer cells without affecting tissue volumes in the cortical section of the tibia. (C) Graph showing reduced bone volume percentage with intra-tibial RM1 cells injection, which was rescued with IPA-3 treatment. (D) Graph showing significantly reduced trabecular thickness with intra-tibial RM1 cell injection, which was rescued with IPA-3 treatment. (E) Bar graph showing that there was no change in trabecular number [plate model] between the groups. (N=10). Data are presented as mean ± SEM. *p < 0.05; $p < 0.01; #p < 0.001. Unpaired Student’s t-test was used to compare between two groups and One-way ANOVA-Ordinary for more than two groups. BV=Bone Volume, TV=Tissue Volume.

Article Snippet: Cell culture The murine metastatic PCa RM1 cell line (CRL-3310) was obtained from ATCC (Manassas, VA).

Techniques: Injection